yuyu
Lv1
60 积分
2023-09-17 加入
-
Emerging role of monoclonal antibodies in the treatment of IgA nephropathy
13天前
已完结
-
POS-132 TRIAL DESIGN: PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF NARSOPLIMAB SAFETY AND EFFICACY IN IGA NEPHROPATHY (ARTEMIS-IGAN)
13天前
已完结
-
Intensive blood pressure control and the progression of IgA nephropathy: a cohort study using marginal structural models
1个月前
已完结
-
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial
2个月前
已完结
-
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
2个月前
已完结
-
POS-109 INTERIM RESULTS OF PHASE 1 AND 2 TRIALS TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL ACTIVITY OF BION-1301 IN PATIENTS WITH IgA NEPHROPATHY
2个月前
已完结
-
POS-109 Interim results of Phase 1 and 2 trials to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of BION-1301 in patients with IgA nephropathy
2个月前
已关闭
-
Is rituximab effective in childhood nephrotic syndrome? Yes and no
3个月前
已完结
-
Obinutuzumab in Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome in Children
4个月前
已完结
-
Crescentic lesions in IgA nephropathy: Impact on outcome
5个月前
已关闭